Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Jun 07, 2024 11:23am
143 Views
Post# 36077642

RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep can provide a fine T-cell boost for ADCs

RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep can provide a fine T-cell boost for ADCs
Doing comparisons it would be nice if onc is being considered for a BO as opposed to a partnership as it ends all uncertainty surrounding the company.
As to IMmunoGEn, I believe that they were worth in the billions before being acquired from looking at ther chart so hard to compare that with onc which at this time is trading under 100 million U.S.
I think most would be happy if we got anything north of 2 billion considering all that the company has been through. Hard to say what the inflection point is or will be as there is a lot going on so tough to say when someone will pull the trigger. Originally it was supposed to be Aware1, then Bracelet, then Goblet, then OS for the MBC and now maybe the FDA type C meeting results.
Something needs to give and soon as bottom line they either need a partnerhsip to fund the phase 3 trials or they need a BO.
<< Previous
Bullboard Posts
Next >>